Dimethylformamide dimethyl acetal → HCID 68313024, 화합물
반응식
[CH:1]([N:4]1[C:8]([C:9]2[N:10]=[C:11]3[C:17]4[CH:18]=[CH:19][C:20]([C:22](=[O:24])[CH3:23])=[CH:21][C:16]=4[O:15][CH2:14][CH2:13][N:12]3[CH:25]=2)=[N:7][C:6]([CH3:26])=[N:5]1)([CH3:3])[CH3:2].CO[CH:29](OC)[N:30]([CH3:32])[CH3:31]>>[CH3:29][N:30]([CH3:32])/[CH:31]=[CH:23]/[C:22]([C:20]1[CH:19]=[CH:18][C:17]2[C:11]3[N:12]([CH:25]=[C:9]([C:8]4[N:4]([CH:1]([CH3:3])[CH3:2])[N:5]=[C:6]([CH3:26])[N:7]=4)[N:10]=3)[CH2:13][CH2:14][O:15][C:16]=2[CH:21]=1)=[O:24]참가 물질
3
실험 절차
1-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)ethanone (2.6 g, 0.0074 mol) and 1,1-Dimethoxy-N,N-dimethylmethanamine (0.98 mL, 0.0074 mol) was mixed in Xylenes (30 mL, 0.07 mol) and was heated to reflux and stirred overnight. LCMS showed complete conversion to desired product. The solvent was removed and (E)-3-(dimethylamino)-1-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)prop-2-en-1-one was used in the next step without further purification.
후처리
- temperaturewas heated
- temperatureto reflux
출처 및 근거
- ORD 기록
- ord-724b190d7d8845f7a6d29f175d1af51e
- 출처 데이터셋
- uspto-grants-2015_07
- 특허 번호
- US09090628B2
반응 노트
불러오는 중…